Comparison of Cabergoline with Quinagolide in Prevention of Severe Ovarian Hyperstimulation Syndrome among Patients Undergoing Intracytoplasmic Sperm Injection:A randomized trial

Authors

  • Anahita Taheripanah Department of Molecular and Cellular Sciences, Faculty of Advanced Sciences and Technology Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
  • Mahshid Vasef 11nfertility and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Marzieh Zamaniyan Infertility Center, Department of Obstetrics and Gynecology, Mazandaran University of Medical Sciences, Sari, Iran.3Diabetes research Center, Mazandaran University of Medical Sciences, Sari, Iran.
  • Robabeh Taheripanah Infertility and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:

a:4:{s:9:"Objective";s:192:"The aim of the present study was to compare Quinagolide with Cabergoline in prevention of ovarian hyper stimulation syndrome among high risk women undergoing intra cytoplasmic sperm injection.";s:19:"MaterialsAndMethods";s:948:"Material and Methods: This Randomized clinical trial study was performed from March 2015 to February 2017. One hundred and twenty six women undergoing ICSI and at high risk of developing ovarian hyperstimulation syndrome (>20follicles>12mm developed), were randomized into two groups. The first group received Cabergoline 0.5mg and the second group received Quinagolide 75mg every day for 7 days commencing on the day of GnRH agonist administration. Then ovarian hyperstimulation syndrome symptoms as well as its severity were assessed according to standard definition 3and 6 days after GnRH agonist administration. Ascites was determined by trans-vaginal ultrasound. Other secondary points were number of oocytes, number of embryos and their quality. Quantitative and qualitative data were analyzed using Student's t test, and Chi-square or fisher’s exact test, respectively. A P-value of less than 0.05 was considered statistically significant.";s:7:"Results";s:734:"Results: The incidence of severe ovarian hyperstimulation syndrome in the Quinagolide group was 3.1% while it was 15.8% in Cabergoline group (p

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Comparison of Cabergoline and Quinagolide in Prevention of Severe Ovarian Hyperstimulation Syndrome among Patients Undergoing Intracytoplasmic Sperm Injection

Background The aim of the current study is to compare quinagolide with cabergoline in prevention of ovarian hyperstimulation syndrome (OHSS) among high risk women undergoing intracytoplasmic sperm injection (ICSI). MATERIALS AND METHODS This randomized clinical trial study was performed from March 2015 to February 2017. One hundred and twenty six women undergoing ICSI who were at high risk of...

full text

comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study

background:   objective: comparison of albumin and cabergoline in the prevention of ohss.   materials and methods: 95 high risk infertile women for ohss (more than 20 follicles in both ovaries at day of human chorionic gonadotropin (hcg) injection) were randomly divided into two groups. first group including 48 women received 10 unit intravenous albumin at starting oocyte retrieval, and second ...

full text

Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study

BACKGROUND Ovarian hyperstimulation syndrome (OHSS) is the most serious and potentially life-threatening iatrogenic complication associated with ovarian stimulation during Assisted Reproductive Technology (ART) protocols. OHSS typically is a result of ovarian expression of vascular endothelial growth factor (VEGF) which increases vascular permeability. OBJECTIVE Comparison of albumin and cabe...

full text

Cabergoline versus Coasting in the Prevention of Ovarian Hyperstimulation Syndrome and Assisted Reproductive Technologies Outcome in High Risk Patients

Background Coasting is the most common method used in the prevention of ovarian hyperstimulation syndrome (OHSS) acting through vascular endothelial growth factor (VEGF) reduction. However, the pregnancy rate is reported to fall with coasting when it takes more than three days. Recently lowdose cabergoline, a selective D2 dopamine receptor agonist has been proven to selectively reduce vascular ...

full text

The Effectiveness of Cabergoline for the Prevention of Ovarian Hyperstimulation Syndrome

Type 2 receptors for vascular endothelial growth factor are believed to be involved in the pathophysiology of ovarian hyperstimulation syndrome (OHSS). The objective of this study was to examine the preventive effects of cabergoline on OHSS and its complications. The study is a non randomized clinical trial conducted in 2006-2008 on 75 patients, which were at risk of OHSS and underwent assisted...

full text

GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial

BACKGROUND The aim of this study was to compare the efficacy of antagonist rescue protocol (replacing GnRH agonist with GnRH antagonist and reducing the dose of gonadotropins) combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome (OHSS) in patients pretreated with GnRH agonist long protocol who were at high risk for OHSS. METHODS Two hundred...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 12  issue 1

pages  1- 5

publication date 2018-06-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023